CLX

Business profile & competitive position

The Clorox Company operates in the Consumer Defensive sector under the Household & Personal Products industry. Its business is the manufacturing and marketing of branded consumer and professional products, with a portfolio that includes Clorox bleach and disinfectants, Pine-Sol, Glad bags and wraps, Fresh Step cat litter, Kingsford charcoal, Hidden Valley dressings, Brita water filtration, Burt’s Bees personal care, and professional health and hygiene brands such as Purell, CloroxPro, and Clorox Healthcare. Following the April 2026 acquisition of GOJO Industries, Clorox expanded its health and hygiene footprint and strengthened its business-to-business presence.

The company’s fiscal 2026 net sales reached $6.7 billion, supported by roughly 9,200 employees operating in approximately 25 countries and selling into about 95 markets. From a moat perspective, Clorox relies on decades of brand recognition, shelf-space relationships, and repeat-purchase demand rather than a structurally high margin. The reported net margin of 8.7% is healthy but not exceptional for the sector; it is consistent with a branded consumer-staples business that competes on marketing, distribution reach, and price points rather than a scarcity-driven cost advantage. The ROE of -1893.5% is a balance-sheet artifact rather than an operational signal: it typically appears when shareholder equity is compressed or negative, which can happen after aggressive share buybacks, accumulated losses, or liability-heavy capital structures. The more relevant competitive read is concentration risk: Walmart accounted for 26% of consolidated FY2026 net sales, and the five largest customers represented about half of consolidated net sales. That dependency is a real feature of the competitive position in modern grocery and mass retail.

Financial posture

Clorox currently trades with a market capitalization of $12.8 billion, a trailing P/E of 22.0, and a low-volatility beta of 0.54. The stock was last at $106.14, sitting above the 50-day EMA of $99.79, with an RSI near neutral-to-warm at 61.5. A P/E of 22.0 places the valuation slightly above the long-run market average but broadly in line with premium consumer-staples names that investors treat as defensive cash-flow stories. The beta of 0.54 confirms that behavior: the stock has historically moved roughly half as much as the broad market, fitting its sector classification as Consumer Defensive.

Profitability at the operating level is best judged by the 8.7% net margin rather than the distorted ROE figure. The negative ROE does raise balance-sheet questions, though it is not by itself evidence of impaired cash generation. For readers comparing Clorox to peers, the key metrics to track are the margin trajectory, cash conversion, and leverage—not the headline ROE. The current price level, sitting about 6.4% above the 50-day EMA, reflects recent post-earnings buying interest rather than a deep-value entry point.

Strategic priorities & outlook

The company’s most recent 10-K lays out a clear set of priorities centered on its IGNITE strategy. The four stated choices are: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. Those themes translate into several operational initiatives that management explicitly calls out.

First, Clorox is working to complete and optimize a new enterprise resource planning (ERP) system as part of a broader digital transformation. The goal is long-term efficiency across supply chain, digital commerce, innovation, and brand building. Investors should note that ERP transitions can create short-term noise: fiscal 2026 earnings were already affected by ERP timing that pulled some sales into fiscal 2025, contributing to a 26% decline in diluted EPS for the year.

Second, the company is prioritizing brand strength, strategic digital capabilities, and a streamlined operating model to build resilience and deliver consistent, profitable growth. Third, it is advancing health and hygiene expansion and portfolio optimization, which includes integrating the GOJO acquisition and growing professional and institutional markets. A related portfolio move occurred on January 31, 2026, when the Glad bags and wraps venture with Procter & Gamble expired. Clorox purchased P&G’s 20% interest, and Glad retained core intellectual property licenses on a royalty-free basis going forward.

Macro & geopolitical exposure

Because Clorox is classified as Consumer Defensive / Household & Personal Products, the macro sensitivities that matter most are those that hit branded household goods broadly. Input-cost inflation is the most direct channel: Clorox uses resins, chemicals, paper pulp, packaging materials, and transportation services, all of which fluctuate with energy prices and commodity markets. Persistent inflation in these categories compresses margins unless the company can push through price increases without losing volume.

Currency exposure is also material for a multinational with sales in roughly 95 markets; a stronger U.S. dollar reduces the translated value of overseas revenue and can pressure reported earnings even when local operations are stable. Regulatory risk sits at the product level as well: disinfectants and sanitizers face EPA and FDA oversight, while food-contact items, personal-care formulations, and product-labeling requirements are subject to shifting consumer-product safety rules.

Trade policy matters through tariffs on imported raw materials and packaging, and through any disruption to global supply chains. Finally, retailer concentration—Walmart alone at 26% and the top five customers near 50%—gives large buyers meaningful bargaining power over pricing, shelving, and promotion terms.

Recent developments

The most recent news cluster centers on Clorox’s Q4 fiscal 2026 report, released around August 4, 2026. Zacks reported that “Clorox Q4 Earnings & Sales Top Estimates as GOJO Supports Sales” on August 4, highlighting that the GOJO acquisition contributed to top-line momentum. The same day, Zacks also noted that the “CLX Q4 Earnings Call Flags Inflation as Share Recovery Builds,” suggesting management was simultaneously celebrating better results and warning that cost pressures remain part of the story. Benzinga added on August 4 that “These Analysts Boost Their Forecasts On Clorox Following Better-Than-Expected Q4 Results,” indicating that sell-side models moved higher after the print.

Heading into the release, a value-comparison piece published on August 6, 2026 by Zacks asked “NWL vs. CLX: Which Stock Is the Better Value Option?” That framing fits the broader theme of investors reassessing consumer-staples valuations after Clorox’s Q4 beat and the subsequent analyst estimate revisions.

Earnings behavior & post-earnings drift

Clorox has a solid earnings track record over the last eight reported quarters, with a beat rate of 6/8 (75%) and an average earnings surprise of 9.4%. The average 5-day post-earnings move is +1.67%, classified as an upward drift. That combination—a high beat rate plus positive average drift—is the profile traders typically associate with a stock that rewards earnings outperformance.

However, the last four quarters show the relationship between beats and price reaction is not mechanical. In the most recent quarter, reported August 3, 2026, Clorox earned $1.66 per share against an estimate of $1.64, a modest 1.2% surprise, and the stock rose 6.52% the next day and 9.61% over the following five days. By contrast, the April 30, 2026 quarter delivered a larger beat—$1.64 vs. $1.55, a 5.8% surprise—yet the stock fell 9.67% the next session and 4.49% over the next five days. That disconnect likely reflects the broader narrative around guidance, inflation, and forward expectations rather than the quarter’s numbers alone.

The February 3, 2026 quarter was the only recent miss, with EPS of $1.39 against an estimate of $1.43, a -2.8% surprise; nevertheless, the stock climbed 2.43% the next day and 5.63% over five days. The November 3, 2025 quarter produced a $0.85 print versus a $0.818 estimate, a 3.9% beat, but the stock only rose 1.17% the next day before slipping 4.08% over the following week.

The next scheduled earnings release is set for November 3, 2026, after the close, with the official consensus EPS estimate at $1.07. Given the historical beat rate and average post-earnings drift, the market will likely be watching whether management commentary can sustain the positive momentum from the August quarter while addressing lingering inflation and ERP-transition headwinds.

For a deeper dive into how institutional analysts are currently weighing growth, valuation, and risk for Clorox, readers should explore the full institutional verdict rather than relying on headline figures alone.